Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
Abstract Background This study was conducted to identify factors associated with the safety and effectiveness of pembrolizumab in Japanese patients with unresectable urothelial carcinoma and to confirm the real-world safety and effectiveness of pembrolizumab in Japanese patients. Methods This multic...
Main Authors: | Hiroyuki Nishiyama, Yu Tanaka, Masahiro Hamada, Masahiko Ozaki, Toshihiko Minegishi, Yuichiro Ito, Shinichiroh Maekawa, Nobuyuki Yamamoto |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-06-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-023-10930-2 |
Similar Items
-
Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
by: Zili Hu, et al.
Published: (2024-11-01) -
A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma
by: Yousuke Fukiishi, et al.
Published: (2023-03-01) -
Pembrolizumab with external radiation therapy effectively controlled TMB-high unresectable recurrent parathyroid cancer: a case report with review of literature
by: Hiroshi Katoh, et al.
Published: (2024-11-01) -
Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
by: Francesca Zacchi, et al.
Published: (2025-02-01) -
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
by: Irfan Cicin, et al.
Published: (2024-07-01)